Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113462 | 1.00 | POLB (0.55) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL6125453 | 0.98 | POLB (0.52) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL6113650 | 0.89 | — | — | |
| SCHEMBL6113435 | 0.82 | ALDH1A1 (0.44) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL6113570 | 0.80 | ALDH1A1 (0.43) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL31120358 | 0.75 | POLB (0.59) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL3726927 | 0.69 | ALDH1A1 (1.00) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL3726934 | 0.69 | ALDH1A1 (1.00) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL3723160 | 0.69 | ALDH1A1 (1.00) | POLBALDH1A1KMT2AHPGDLMNA | |
| SCHEMBL13928854 | 0.69 | SMN1; SMN2 (0.50) | POLBALDH1A1KMT2AHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | POLB 1411/4885ALDH1A1 723/4885KMT2A 1131/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | POLB 2220/4885ALDH1A1 766/4885KMT2A 1209/4885 |
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | POLB 2658/4885ALDH1A1 477/4885KMT2A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.